Connect with us

Headlines

Alcon to Acquire Eysuvis Drops for Dry Eye Treatment

Alcon will pay $60M in upfront consideration.

mm

Published

on

GENEVA — Alcon has signed an agreement to acquire Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals Inc.

The acquisition of the eye drops (0.25% loteprednol etabonate suspension) “will complement Alcon’s existing portfolio in the large and fast-growing dry eye category,” according to a press release.

Alcon will pay $60 million in upfront consideration to Kala. Alcon “may be required to make additional contingent payments upon achievement of certain commercial milestones,” according to the release.

The transaction is anticipated to close in the third quarter.

More from the release:

EYSUVIS will complement the Systane family of eye drops which includes the recently launched Systane Preservative-Free formulations now available in a convenient, multi-dose bottle. While the Systane family is used for ongoing management of dry eye symptoms, EYSUVIS will provide Eye Care Professionals (ECPs) with an option for short-term treatment to mitigate dry eye disease.

Over 30 million people in the United States suffer from dry eye. Alcon research shows that about 20-25% of dry eye patients experience acute episodes of dry eye on average twice per year. EYSUVIS, a corticosteroid, may be prescribed by ECPs during these episodes of acute dry eye.

EYSUVIS was approved by the U.S. Food & Drug Administration in January 2021 as the first-and-only corticosteroid indicated for up to two weeks of treatment of the signs and symptoms of dry eye disease. The prescription therapy utilizes a proprietary drug delivery technology known as AMPPLIFY to enhance penetration of loteprednol etabonate into targeted tissue on the ocular surface, helping to prevent flares associated with dry eye disease.

“We will be pleased to add EYSUVIS to our growing pharmaceutical portfolio,” said Sergio Duplan, President, North America at Alcon. “EYSUVIS is a natural fit for our newly formed ophthalmic eye drop sales force in the United States. With our strong expertise in market access and commercial execution, we are well-positioned to build the market for acute dry eye treatment.”

As part of the agreement, Alcon will also acquire INVELTYS (loteprednol etabonate suspension) 1%, the only corticosteroid for twice-a-day treatment of post-operative inflammation and pain following ocular surgery.

Advertisement

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at [email protected].

SPONSORED VIDEO

Varilux Young Presbyope Testimonial Video

Your patients are noticing presbyopia symptoms earlier in life, but it doesn’t have to keep them from enjoying the things they love. People in their 40s – the generation that embraced life and work online – have helped us see the world in new and exciting ways, and they need a vision solution that doesn’t slow them down: Varilux® progressive lenses. See how to start the conversation with your patients today at essilorpro.com/welcome-to-presbyopia.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular